-- Stifel Canada指出，尽管宏观经济波动，Cargojet (CJT.TO) 第一季度业绩依然稳健，这主要得益于国内航线网络的良好表现以及南美/中美洲新包机业务的增长。 分析师Daryl Young维持对该公司股票的“买入”评级，目标价为120美元。他指出，初步来看，Cargojet调整后的EBITDA为8190万美元，比市场预期高出4.9%。 管理层给出了积极的展望，国内航线网络在4月份表现良好，而新增的包机客户和航线预计将缓解全年传统的季节性波动。 去年11月MD-11飞机停飞带来的相关收入预计将持续到今年第三季度。Young补充道，国际飞机、机组人员、维护和保险（ACMI）业务仍然低迷，但南北航线似乎已经找到了新的增长点（东西航线仍需一段时间才能恢复）。 “总体而言，我们仍然认为 CJT 在应对当前低迷的市场环境方面做得很好，随着关税/贸易不利因素最终消退，其基本面和股价有望上涨。”
Price: $82.17, Change: $+4.47, Percent Change: +5.75%
Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%
Price: $15.79, Change: $-4.34, Percent Change: -21.55%
Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%